Yıl: 2023 Cilt: 22 Sayı: 2 Sayfa Aralığı: 62 - 67 Metin Dili: İngilizce DOI: 10.4274/uob.galenos.2023.2023.1.4 İndeks Tarihi: 04-07-2023

Treatment of Primary Tumor in Oligometastatic Prostate Cancer: An Observational Study of the Turkish Urooncology Association Prostate Diseases Working Group

Öz:
Objective: To report the clinical results of patients who had metastatic prostate cancer (PC) at admission and underwent standard androgen deprivation therapy with radiotherapy (RT) and radical prostatectomy (RP) for the primary tumor. Materials and Methods: This study used the PC database from the Turkish Urooncology Association, to which participating institutions submit online data. The following clinical, radiological, and pathological findings were retrieved from the database: age, total prostate-specific antigen, clinical TNM stage, number of metastases, International Society of Urological Pathology grade group of biopsy, time to castration-resistant disease, type of local treatment, type of staging method, status of survival, type of systemic treatment, and follow-up time. Results: The median follow-up of the 18 included patients was 59.1 (19.9-180) months. RP and extended lymphadenectomy were performed in 12 patients. RT was performed in 6 patients. The median number of metastases was 2 (1-4) and 3 (1-4) in the RP and RT groups, respectively. In the RP group, 3 of 12 patients developed castration-resistant prostate cancer (CRPC) during the follow-up period. In the RT group, 2 of 6 patients developed CRPC in the follow-up period. The time to CRPC was 48.4 and 43.3 months, respectively. Conclusion: While primary tumor-directed RT is effective in selected patients, the results of prospective randomized controlled studies are required to demonstrate the effectiveness of RP.
Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
0
0
0
  • 1. National Prostate Cancer Audit. Annual Report 2021: results of the NPCA Prospective Audit in England and Wales for men diagnosed from 1 April 2019-31 March 2020 [online]. Available at: https://www. npca.org.uk/content/uploads/2022/01/NPCA-Annual-Report-2021_ Final_13.01.22-1.pdf. Accessed Dec 2022.
  • 2. Siegel DA, O’Neil ME, Richards TB, et ol. Prostate Cancer Incidence and Survival, by Stage and Race/Ethnicity - United States, 2001- 2017. MMWR Morb Mortal Wkly Rep 2020;69:1473-1480.
  • 3. Pagliarulo V, Bracarda S, Eisenberger MA, et al. Contemporary role of androgen deprivation therapy for prostate cancer. Eur Urol 2012;61:11-25.
  • 4. Ryan CJ, Smith MR, de Bono JS, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 2013;368:138-148. Erratum in: N Engl J Med 2013;368:584.
  • 5. Beer TM, Armstrong AJ, Rathkopf DE, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 2014;371:424-433.
  • 6. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351:1502-1512.
  • 7. Terada N, Aizawa R, Nihei K, et al. Narrative review of local prostate and metastasis-directed radiotherapy in the treatment of metastatic prostate cancer. Jpn J Clin Oncol 2022;52:633-641.
  • 8. Hellman S, Weichselbaum RR. Oligometastases. J Clin Oncol 1995;13:8-10.
  • 9. Cetin B, Wabl CA, Gumusay O. Optimal Treatment for Patients with Oligometastatic Prostate Cancer. Urol Int 2022;106:217-226.
  • 10. Epstein JI, Egevad L, Amin MB, et al. The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: Definition of Grading Patterns and Proposal for a New Grading System. Am J Surg Pathol 2016;40:244-252.
  • 11. EAU - EANM - ESTRO - ESUR - ISUP - SIOG Guidelines on Prostate Cancer. 2022 [online]. Available at: https://d56bochluxqnz.cloudfront. net/documents/full-guideline/EAU-EANM-ESTRO-ESUR-ISUP_SIOGGuidelines- on-Prostate-Cancer-2022_2022-04-25-063938_yfos.pdf. Accessed Dec 2022.
  • 12. Sathianathen NJ, Philippou YA, Kuntz GM, et al. Taxane-based chemohormonal therapy for metastatic hormone-sensitive prostate cancer: a Cochrane Review. BJU Int 2019;124:370-372.
  • 13. Davis ID, Martin AJ, Stockler MR, et al. Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer. N Engl J Med 2019;381:121-131.
  • 14. Chi KN, Agarwal N, Bjartell A, et al. Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer. N Engl J Med 2019;381:13-24.
  • 15. Fizazi K, Tran N, Fein L, et al. Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer. N Engl J Med 2017;377:352-360.
  • 16. James ND, de Bono JS, Spears MR, et al. Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy. N Engl J Med 2017;377:338-351.
  • 17. Fizazi K, Foulon S, Carles J, et al. Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, openlabel, randomised, phase 3 study with a 2 x 2 factorial design. Lancet 2022;399:1695-1707.
  • 18. Gafita A, Wang H, Robertson A, et al. Tumor Sink Effect in 68Ga- PSMA-11 PET: Myth or Reality? J Nucl Med 2022;63:226-232.
  • 19. Sweeney CJ, Chen YH, Carducci M, et al. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. N Engl J Med 2015;373:737-746.
  • 20. Bieth M, Krönke M, Tauber R, et al. Exploring New Multimodal Quantitative Imaging Indices for the Assessment of Osseous Tumor Burden in Prostate Cancer Using 68Ga-PSMA PET/CT. J Nucl Med 2017;58:1632-1637.
  • 21. Gafita A, Bieth M, Krönke M, et al. qPSMA: Semiautomatic Software for Whole-Body Tumor Burden Assessment in Prostate Cancer Using 68Ga-PSMA11 PET/CT. J Nucl Med 2019;60:1277-1283.
  • 22. Barbato F, Fendler WP, Rauscher I, et al. PSMA-PET for the assessment of metastatic hormone-sensitive prostate cancer volume of disease. J Nucl Med 2021;62:1747–1750.
  • 23. Boevé LMS, Hulshof MCCM, Vis AN, et al. Effect on Survival of Androgen Deprivation Therapy Alone Compared to Androgen Deprivation Therapy Combined with Concurrent Radiation Therapy to the Prostate in Patients with Primary Bone Metastatic Prostate Cancer in a Prospective Randomised Clinical Trial: Data from the HORRAD Trial. Eur Urol 2019;75:410-418.
  • 24. Parker CC, James ND, Brawley CD, et al. Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. Lancet 2018;392:2353-2366.
  • 25. Burdett S, Boevé LM, Ingleby FC, et al. Prostate Radiotherapy for Metastatic Hormone-sensitive Prostate Cancer: A STOPCAP Systematic Review and Meta-analysis. Eur Urol 2019;76:115-124.
  • 26. Kızılay F. Current Status of Oligometastatic Prostate Cancer: Risk Factors and Treatment Approaches. Bulletin of Urooncology 2018;17:105-112.
  • 27. Shemshaki H, Al-Mamari SA, Geelani IA, Kumar S. Cytoreductive radical prostatectomy versus systemic therapy and radiation therapy in metastatic prostate cancer: A systematic review and meta-analysis. Urologia 2022;89:16-30.
  • 28. Steuber T, Berg KD, Røder MA, et al. Does Cytoreductive Prostatectomy Really Have an Impact on Prognosis in Prostate Cancer Patients with Low-volume Bone Metastasis? Results from a Prospective Case-Control Study. Eur Urol Focus 2017;3:646-649.
  • 29. Phillips R, Shi WY, Deek M, et al. Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer: The ORIOLE Phase 2 Randomized Clinical Trial. JAMA Oncol 2020;6:650-659.
  • 30. Ost P, Reynders D, Decaestecker K, et al. Surveillance or metastasisdirected therapy for oligometastatic prostate cancer recurrence (STOMP): Five-year results of a randomized phase II trial. J Clin Oncol 2018;36:446-453.
APA koparal m, Sozen T, Aslan G, Baltacı S, Erbatu O, Türkeri L (2023). Treatment of Primary Tumor in Oligometastatic Prostate Cancer: An Observational Study of the Turkish Urooncology Association Prostate Diseases Working Group. , 62 - 67. 10.4274/uob.galenos.2023.2023.1.4
Chicago koparal murat yavuz,Sozen Tevfik Sinan,Aslan Guven,Baltacı Sümer,Erbatu Oguzcan,Türkeri Levent Treatment of Primary Tumor in Oligometastatic Prostate Cancer: An Observational Study of the Turkish Urooncology Association Prostate Diseases Working Group. (2023): 62 - 67. 10.4274/uob.galenos.2023.2023.1.4
MLA koparal murat yavuz,Sozen Tevfik Sinan,Aslan Guven,Baltacı Sümer,Erbatu Oguzcan,Türkeri Levent Treatment of Primary Tumor in Oligometastatic Prostate Cancer: An Observational Study of the Turkish Urooncology Association Prostate Diseases Working Group. , 2023, ss.62 - 67. 10.4274/uob.galenos.2023.2023.1.4
AMA koparal m,Sozen T,Aslan G,Baltacı S,Erbatu O,Türkeri L Treatment of Primary Tumor in Oligometastatic Prostate Cancer: An Observational Study of the Turkish Urooncology Association Prostate Diseases Working Group. . 2023; 62 - 67. 10.4274/uob.galenos.2023.2023.1.4
Vancouver koparal m,Sozen T,Aslan G,Baltacı S,Erbatu O,Türkeri L Treatment of Primary Tumor in Oligometastatic Prostate Cancer: An Observational Study of the Turkish Urooncology Association Prostate Diseases Working Group. . 2023; 62 - 67. 10.4274/uob.galenos.2023.2023.1.4
IEEE koparal m,Sozen T,Aslan G,Baltacı S,Erbatu O,Türkeri L "Treatment of Primary Tumor in Oligometastatic Prostate Cancer: An Observational Study of the Turkish Urooncology Association Prostate Diseases Working Group." , ss.62 - 67, 2023. 10.4274/uob.galenos.2023.2023.1.4
ISNAD koparal, murat yavuz vd. "Treatment of Primary Tumor in Oligometastatic Prostate Cancer: An Observational Study of the Turkish Urooncology Association Prostate Diseases Working Group". (2023), 62-67. https://doi.org/10.4274/uob.galenos.2023.2023.1.4
APA koparal m, Sozen T, Aslan G, Baltacı S, Erbatu O, Türkeri L (2023). Treatment of Primary Tumor in Oligometastatic Prostate Cancer: An Observational Study of the Turkish Urooncology Association Prostate Diseases Working Group. Üroonkoloji Bülteni, 22(2), 62 - 67. 10.4274/uob.galenos.2023.2023.1.4
Chicago koparal murat yavuz,Sozen Tevfik Sinan,Aslan Guven,Baltacı Sümer,Erbatu Oguzcan,Türkeri Levent Treatment of Primary Tumor in Oligometastatic Prostate Cancer: An Observational Study of the Turkish Urooncology Association Prostate Diseases Working Group. Üroonkoloji Bülteni 22, no.2 (2023): 62 - 67. 10.4274/uob.galenos.2023.2023.1.4
MLA koparal murat yavuz,Sozen Tevfik Sinan,Aslan Guven,Baltacı Sümer,Erbatu Oguzcan,Türkeri Levent Treatment of Primary Tumor in Oligometastatic Prostate Cancer: An Observational Study of the Turkish Urooncology Association Prostate Diseases Working Group. Üroonkoloji Bülteni, vol.22, no.2, 2023, ss.62 - 67. 10.4274/uob.galenos.2023.2023.1.4
AMA koparal m,Sozen T,Aslan G,Baltacı S,Erbatu O,Türkeri L Treatment of Primary Tumor in Oligometastatic Prostate Cancer: An Observational Study of the Turkish Urooncology Association Prostate Diseases Working Group. Üroonkoloji Bülteni. 2023; 22(2): 62 - 67. 10.4274/uob.galenos.2023.2023.1.4
Vancouver koparal m,Sozen T,Aslan G,Baltacı S,Erbatu O,Türkeri L Treatment of Primary Tumor in Oligometastatic Prostate Cancer: An Observational Study of the Turkish Urooncology Association Prostate Diseases Working Group. Üroonkoloji Bülteni. 2023; 22(2): 62 - 67. 10.4274/uob.galenos.2023.2023.1.4
IEEE koparal m,Sozen T,Aslan G,Baltacı S,Erbatu O,Türkeri L "Treatment of Primary Tumor in Oligometastatic Prostate Cancer: An Observational Study of the Turkish Urooncology Association Prostate Diseases Working Group." Üroonkoloji Bülteni, 22, ss.62 - 67, 2023. 10.4274/uob.galenos.2023.2023.1.4
ISNAD koparal, murat yavuz vd. "Treatment of Primary Tumor in Oligometastatic Prostate Cancer: An Observational Study of the Turkish Urooncology Association Prostate Diseases Working Group". Üroonkoloji Bülteni 22/2 (2023), 62-67. https://doi.org/10.4274/uob.galenos.2023.2023.1.4